Researchers from the University of California and other institutions found that GLP-1 medications, including semaglutide, may slow biological aging markers in people living with HIV. The study, published in May in Nature Communications, observed improvements in biomarkers linked to brain-heart aging and inflammation over a 32-week period.
How Semaglutide Influenced Aging Biomarkers
The study focused on 84 individuals with HIV-associated lipohypertrophy to determine if metabolic interventions could alter the pace of biological decay. According to ThePrint, the researchers divided the group: 45 participants received the active drug semaglutide, while 39 received a placebo.
Over the 32-week trial, those taking the medication showed improvements in biomarkers associated with inflammation and the aging of the heart and brain. This connection exists because metabolic health and biological aging are deeply intertwined. Since GLP-1 drugs improve insulin regulation and metabolic health, they may influence the broader aging process.
Michael Corley, PhD, an associate professor of medicine at the University of California, San Diego’s Stein Institute for Research on Aging, noted that the specific group studied provided a unique scientific window.
“The trial provided us an opportunity to say, hey, is there any signal here that warrants all the hype?”
Michael Corley, via Yahoo Health
Corley described those living with HIV as “a good population” for this research because the disease is often linked to accelerated biological aging.
The Role of Inflammation in Longevity
Photo: Yahoo Health
The potential for GLP-1 drugs to act as longevity tools centers on their ability to combat chronic inflammation. Experts suggest that by reducing the diseases typically linked to aging, these drugs might eventually extend the human lifespan.
Thomas Blackwell, a professor of general internal medicine at the University of Texas Medical Branch in Galveston, highlighted the specific mechanism at play.
“We know they have a significant anti-inflammatory effect, and we know inflammation is one of the things that accelerates aging,”
Thomas Blackwell, via ThePrint
Nicolas Musi, MD, director of the Diabetes and Aging Center at Cedars-Sinai, told Yahoo Health that it is reasonable to believe these medications could improve longevity because they reduce risks for heart disease and diabetes, two primary causes of death.
Risks of Muscle Loss and Bone Density Decline
The SLIM LIVER Study: Use of Semaglutide for Persons with HIV
Despite the promising biomarkers, the medical community warns against using these drugs as a general anti-aging tonic. A primary concern is the nature of the weight loss achieved via GLP-1 receptor agonists. Rapid weight loss can lead to a decrease in muscle mass and a decline in bone density.
These side effects are particularly dangerous for aging populations, as they can increase the risk of frailty and bone-related diseases. Because of this, Dr. Musi does not recommend taking GLP-1 drugs off-label solely for the purpose of living longer.
What the Data Says vs. What Remains Unknown
Photo: ThePrint
There is a significant gap between observing a “signal” in a small, specific group and proving a longevity benefit for the general public. The current evidence is limited by the study’s scope.
Population Limit: The trial only included people with HIV and lipohypertrophy; it did not study healthy individuals without HIV.
Sample Size: The study relied on a small group of 84 people.
Lifespan Evidence: There is currently little evidence that these drugs extend the actual lifespan of otherwise healthy people.
The researchers emphasized that more rigorous data is required before these drugs can be classified as “gerotherapeutics.”
“Prospective trials are needed to determine whether GLP-1 receptor agonists can be repurposed as gerotherapeutics”
Study finding, via ThePrint
Future Clinical Trials and Longevity Outlook
The medical community is now moving toward broader clinical trials to quantify the impact of GLP-1 drugs on specific age markers. These upcoming studies will focus on:
Inflammation levels
Metabolic rate
Muscle strength
Walking speed and mobility
While the potential to slow biological aging is a compelling prospect, results from these expanded trials are still years away. For those seeking longevity today, health experts maintain that the basics—nutrition, physical activity, quality sleep, and avoiding smoking—remain the most effective proven strategies. Anyone considering GLP-1 medication should consult a healthcare provider to determine if they meet approved medical criteria.
Jonathan has a background in public health journalism and medical reporting. He manages the health section with a focus on clarity, responsible sourcing, and reader understanding of medical and wellness topics.
